SMMT - Summit Therapeutics Inc.

14.94
-0.440   -2.945%

Share volume: 2,431,342
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$15.38
-0.44
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 22%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.72%
1 Month
-0.33%
3 Months
-19.79%
6 Months
-23.17%
1 Year
-21.33%
2 Year
-18.36%
Key data
Stock price
$14.94
P/E Ratio 
0.00
DAY RANGE
$14.67 - $15.15
EPS 
-$0.76
52 WEEK RANGE
$13.83 - $36.91
52 WEEK CHANGE
-$15.97
MARKET CAP 
13.020 B
YIELD 
N/A
SHARES OUTSTANDING 
775.373 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$2,072,192
AVERAGE 30 VOLUME 
$2,239,171
Company detail
CEO: Robert W. Duggan
Region: US
Website: summittxinc.com
Employees: 110
IPO year: 2015
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Summit Therapeutics Inc. conducts clinical programs focusing on Clostridioides difficile infection (CDI) The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Recent news